These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 29142197)

  • 1. Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells.
    Imperlini E; Gnecchi M; Rognoni P; Sabidò E; Ciuffreda MC; Palladini G; Espadas G; Mancuso FM; Bozzola M; Malpasso G; Valentini V; Palladini G; Orrù S; Ferraro G; Milani P; Perlini S; Salvatore F; Merlini G; Lavatelli F
    Sci Rep; 2017 Nov; 7(1):15661. PubMed ID: 29142197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis.
    Lavatelli F; Imperlini E; Orrù S; Rognoni P; Sarnataro D; Palladini G; Malpasso G; Soriano ME; Di Fonzo A; Valentini V; Gnecchi M; Perlini S; Salvatore F; Merlini G
    FASEB J; 2015 Nov; 29(11):4614-28. PubMed ID: 26220173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity.
    Guan J; Mishra S; Shi J; Plovie E; Qiu Y; Cao X; Gianni D; Jiang B; Del Monte F; Connors LH; Seldin DC; Lavatelli F; Rognoni P; Palladini G; Merlini G; Falk RH; Semigran MJ; Dec GW; Macrae CA; Liao R
    Basic Res Cardiol; 2013 Sep; 108(5):378. PubMed ID: 23982491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Internalisation of immunoglobulin light chains by cardiomyocytes in AL amyloidosis: what can biopsies tell us?
    Bézard M; Zaroui A; Kharoubi M; Lam F; Poullot E; Teiger E; Agbulut O; Damy T; Kordeli E
    Amyloid; 2024 Sep; 31(3):209-219. PubMed ID: 38973117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inherent Biophysical Properties Modulate the Toxicity of Soluble Amyloidogenic Light Chains.
    Maritan M; Romeo M; Oberti L; Sormanni P; Tasaki M; Russo R; Ambrosetti A; Motta P; Rognoni P; Mazzini G; Barbiroli A; Palladini G; Vendruscolo M; Diomede L; Bolognesi M; Merlini G; Lavatelli F; Ricagno S
    J Mol Biol; 2020 Feb; 432(4):845-860. PubMed ID: 31874151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesenchymal stromal cells protect human cardiomyocytes from amyloid fibril damage.
    Lin Y; Marin-Argany M; Dick CJ; Redhage KR; Blancas-Mejia LM; Bulur P; Butler GW; Deeds MC; Madden BJ; Williams A; Wall JS; Dietz A; Ramirez-Alvarado M
    Cytotherapy; 2017 Dec; 19(12):1426-1437. PubMed ID: 29037943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?
    Zhang C; Huang X; Li J
    Blood Rev; 2017 Jul; 31(4):261-270. PubMed ID: 28336182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study.
    Ami D; Lavatelli F; Rognoni P; Palladini G; Raimondi S; Giorgetti S; Monti L; Doglia SM; Natalello A; Merlini G
    Sci Rep; 2016 Jul; 6():29096. PubMed ID: 27373200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity.
    Oberti L; Rognoni P; Barbiroli A; Lavatelli F; Russo R; Maritan M; Palladini G; Bolognesi M; Merlini G; Ricagno S
    Sci Rep; 2017 Dec; 7(1):16809. PubMed ID: 29196671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient.
    Swuec P; Lavatelli F; Tasaki M; Paissoni C; Rognoni P; Maritan M; Brambilla F; Milani P; Mauri P; Camilloni C; Palladini G; Merlini G; Ricagno S; Bolognesi M
    Nat Commun; 2019 Mar; 10(1):1269. PubMed ID: 30894521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity.
    Martin EB; Williams A; Wooliver C; Heidel RE; Adams S; Dunlap J; Ramirez-Alvarado M; Blancas-Mejia LM; Lands RH; Kennel SJ; Wall JS
    PLoS One; 2017; 12(3):e0174152. PubMed ID: 28350808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress.
    Brenner DA; Jain M; Pimentel DR; Wang B; Connors LH; Skinner M; Apstein CS; Liao R
    Circ Res; 2004 Apr; 94(8):1008-10. PubMed ID: 15044325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis.
    Lavatelli F; Mazzini G; Ricagno S; Iavarone F; Rognoni P; Milani P; Nuvolone M; Swuec P; Caminito S; Tasaki M; Chaves-Sanjuan A; Urbani A; Merlini G; Palladini G
    J Biol Chem; 2020 Dec; 295(49):16572-16584. PubMed ID: 32952127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosis.
    Klimtchuk ES; Prokaeva TB; Spencer BH; Gursky O; Connors LH
    Amyloid; 2017 Jun; 24(2):115-122. PubMed ID: 28632419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity.
    Guan J; Mishra S; Qiu Y; Shi J; Trudeau K; Las G; Liesa M; Shirihai OS; Connors LH; Seldin DC; Falk RH; MacRae CA; Liao R
    EMBO Mol Med; 2014 Nov; 6(11):1493-507. PubMed ID: 25319546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A constant domain mutation in a patient-derived antibody light chain reveals principles of AL amyloidosis.
    Rottenaicher GJ; Absmeier RM; Meier L; Zacharias M; Buchner J
    Commun Biol; 2023 Feb; 6(1):209. PubMed ID: 36823438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoglobulin light chain amyloid aggregation.
    Blancas-Mejia LM; Misra P; Dick CJ; Cooper SA; Redhage KR; Bergman MR; Jordan TL; Maar K; Ramirez-Alvarado M
    Chem Commun (Camb); 2018 Sep; 54(76):10664-10674. PubMed ID: 30087961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloidogenic light chains impair plasma cell survival.
    Pick M; Lebel E; Elgavish S; Benyamini H; Nevo Y; Hertz R; Bar-Tana J; Rognoni P; Merlini G; Gatt ME
    Haematologica; 2023 Dec; 108(12):3359-3371. PubMed ID: 37381778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of human amyloidogenic light chains causes heart failure in embryonic zebrafish: a preliminary report.
    Shin JT; Ward JE; Collins PA; Dai M; Semigran HL; Semigran MJ; Seldin DC
    Amyloid; 2012 Dec; 19(4):191-6. PubMed ID: 23126591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Ultrastructure of Tissue Damage by Amyloid Fibrils.
    Koike H; Katsuno M
    Molecules; 2021 Jul; 26(15):. PubMed ID: 34361762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.